Acquisition of pioneering biomarker technology company Definiens strengthens personalised healthcare capabilities

We have been working closely with the MedImmune team on tissue phenomics. Together, we're extracting information from tissue images to find novel markers for patient stratification by correlating tissue information with clinical outcomes. Sharing expertise allows MedImmune and Definiens to bring tailored treatments to patients faster.

Thomas Heydler, Chief Executive Officer Definiens